Ryo Watanabe
Tohoku University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ryo Watanabe.
Journal of Neuroscience Research | 2012
Morin Ryu; Masayuki Yasuda; Dong Shi; Ahmed Y. Shanab; Ryo Watanabe; Noriko Himori; Kazuko Omodaka; Yu Yokoyama; Jiro Takano; Takaomi C. Saido; Toru Nakazawa
Calpain, an intracellular cysteine protease, has been widely reported to be involved in neuronal cell death. The purpose of this study is to investigate the role of calpain activation in axonal damage‐induced retinal ganglion cell (RGC) death. Twelve‐week‐old male calpstatin (an endogenous calpain inhibitor) knockout mice (CAST KO) and wild‐type (WT) mice were used in this study. Axonal damage was induced by optic nerve crush (NC) or tubulin destruction induced by leaving a gelatin sponge soaked with vinblastine (VB), a microtubule disassembly chemical, around the optic nerve. Calpain activation was assessed by immunoblot analysis, which indirectly quantified the cleaved α‐fodrin, a substrate of calpain. RGCs were retrogradely labeled by injecting a fluorescent tracer, Fluoro‐Gold (FG), and the retinas were harvested and flat‐mounted retinas prepared. The densities of FG‐labeled RGCs harvested from the WT and CAST KO groups were assessed and compared. Additionally, a calpain inhibitor (SNJ‐1945, 100 mg/kg/day) was administered orally, and the density of surviving RGCs was compared with that of the vehicle control group. The mean density of surviving RGCs in the CAST KO group was significantly lower than that observed in the WT group, both in NC and in VB. The mean density of surviving RGCs in the SNJ‐1945‐treated group was significantly higher than that of the control group. The calpain inhibitor SNJ‐1945 has a neuroprotective effect against axonal damage‐induced RGC death. This pathway may be an important therapeutic target for preventing this axonal damage‐induced RGC death, including glaucoma and diabetic optic neuropathy and other CNS diseases that share a common etiology.
Neurobiology of Disease | 2012
Ahmed Y. Shanab; Toru Nakazawa; Morin Ryu; Yuji Tanaka; Noriko Himori; Keiko Taguchi; Masayuki Yasuda; Ryo Watanabe; Jiro Takano; Takaomi C. Saido; Naoko Minegishi; Toshio Miyata; Toshiaki Abe; Masayuki Yamamoto
To describe how a high fat diet (HFD) and hyperglycemia initiate a sequence of calpain activation and oxidative stress associated with neuro-degenerative changes in diabetic retinopathy (DR), hyperglycemia was induced with streptozotocin in mice lacking the gene for calpastatin (CAST KO), and in mice lacking the gene for the transcription factor NF-E2 related factor 2 (Nrf2 KO). All animals were fed a HFD. Retinal ganglion cell (RGC) density was estimated by labeling with fluorogold and immunohistochemistry. A potent calpain inhibitor, SNJ-1945, was administered daily until the animals were sacrificed. In vitro, oxidative stress-induced RGC loss was evaluated in a high glucose culture medium with and without SNJ-1945. Retinal mRNA of calpain-1 and calpain-2 was measured by quantitative RT-PCR. Pre-apoptotic substrates of cleaved α-fodrin and synaptophysin protein were quantified by immunoblot analysis. Axonal damage was examined in transverse sections of the optic nerve. A HFD and hyperglycemia significantly increased RGC and axonal degeneration 3 weeks into the experiment. Levels of cleaved α-fodrin were increased. In the CAST KO mice, the neurotoxicity was augmented significantly. Gene manipulation of CAST and orally administered SNJ-1945 successfully modified calpain levels in the retina and prevented RGC death. In vitro, a high-glucose culture of retinal cells without antioxidants showed more RGC death than that with antioxidant treatment. The expression of synaptophysin was significantly suppressed by SNJ-1945 treatment. These results suggest that calpain plays a crucial role in metabolic-induced RGC degeneration caused by hyperglycemia and oxidative stress. Antioxidant and calpain inhibition offers important opportunities for future neuroprotective treatment against RGC death in various metabolic stress-induced diseases including DR.
Biochemical and Biophysical Research Communications | 2015
Hirotaka Kanoh; Takayuki Kuraishi; Li-Li Tong; Ryo Watanabe; Shinji Nagata; Shoichiro Kurata
Damage-associated molecular patterns (DAMPs), so-called danger signals, play important roles in host defense and pathophysiology in mammals and insects. In Drosophila, the Toll pathway confers damage responses during bacterial infection and improper cell-fate control. However, the intrinsic ligands and signaling mechanisms that potentiate innate immune responses remain unknown. Here, we demonstrate that a Drosophila larva-derived tissue extract strongly elicits Toll pathway activation via the Toll receptor. Using this extract, we performed exxa0vivo genome-wide RNAi screening in Drosophila cultured cells, and identified several signaling factors that are required for host defense and antimicrobial-peptide expression in Drosophila adults. These results suggest that our larva-derived tissue extract contains active ingredients that mediate Toll pathway activation, and the screening data will shed light on the mechanisms of damage-related Toll pathway signaling in Drosophila.
Chemical & Pharmaceutical Bulletin | 1986
Takao Sakamoto; Yoshinori Kondo; Ryo Watanabe; Hiroshi Yamanaka
Chemical & Pharmaceutical Bulletin | 1989
Yoshinori Kondo; Ryo Watanabe; Takao Sakamoto; Hiroshi Yamanaka
Chemical & Pharmaceutical Bulletin | 1989
Yoshinori Kondo; Ryo Watanabe; Takao Sakamoto; Hiroshi Yamanaka
Yakugaku Zasshi-journal of The Pharmaceutical Society of Japan | 1989
Shoetsu Konno; Mamoru Tsunoda; Ryo Watanabe; Hiroshi Yamanaka; Fumio Fujita; Norio Ohtsuka; Shoji Asano
Archive | 2010
Kohji Nishida; Ryuhei Hayashi; Ryo Watanabe; Yasuhiko Tabata
Journal of Chemical Engineering of Japan | 2010
Ryo Watanabe; Tomoyuki Shindoh; Yohsuke Matsushita; Hideyuki Aoki; Takatoshi Miura; Katsuya Nishiwaki; Hiroshi Yamada; Okiteru Fukuda; Togo Yamaguchi
Yakugaku Zasshi-journal of The Pharmaceutical Society of Japan | 1989
Shoetsu Konno; Ryo Watanabe; Hiroshi Yamanaka